Global Urinary Follicle-Stimulating Hormone Market Size, Share, and Trends Analysis Report, By Product (75IU, 150IU, and Others) and By Application (Infertility Treatment and Assisted Reproductive Technology) Forecast Period (2022-2028)  

The global urinary follicle-stimulating hormone market is anticipated to grow at a significant CAGR of 2.5% during the forecast period (2022-2028). Urinary follicle tests are gaining huge traction in young females attributing to high significance in determining menstrual irregularities for different age groups. The rising cases of infertility among men and women  both, as well as rising disposable income and the widespread availability of educated specialists, are driving the growth of the market for urinary follicle-stimulating hormones. The use of fertility testing is also becoming more common as the number of cases of pituitary or hypothalamic problems rises.

The market players are also contributing significantly in the growth of the market by the adoption of various strategies including mergers and acquisitions, geographical expansion, partnerships, collaborations, and new product launches, in order to stay competitive in the market. For instance,

• In December 2021, MFB Fertility, the maker of a line of at-home pregnancy-related hormone tests, received$9.7 million of Series A investment. The financing comes after the FDA premarket approval received by the company for a progesterone urine test and the launch of a mobile app. MFB Fertility is better known as Proov, which is the name of the test that was created by owner and CEO Amy Beckley. The company also offers “full” testing kit that includes PdG, Luteinizing Hormone (LH), and Follicle Stimulating Hormone (FSH) assays.
• In August 2021, Merck Specialties Pvt ltd.launched Pergoveris Pen for advanced infertility therapy. The company’s goal with this launch is to meet unmet medical requirements by providing a better, more convenient, and ready-to-use combo treatment option for women with severe follicle-stimulating hormone (FSH) and luteinizing hormone (LH) deficiencies.  Infertility is prevailing rapidly among Indians and is heavily reliant on a healthy ovulation cycle. Infertility can come from any functional dysfunction of the hypothalamic-pituitary-ovarian axis, which can cause ovulation to be absent or infrequent. After being prescribed by an IVF doctor, the novel Pergoveris Pen allows patients with severe FSH and LH shortage to have a better treatment experience.

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Product
  • By Application
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

· Competitive Landscape- IBSA, Ferring Pharmaceuticals, Livzon Pharmaceutical Group Inc., Teva Pharmaceutical Industries Ltd., and Merck KGaA, among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Urinary Follicle-Stimulating Hormone Market Report by Segment

By Product

• 75IU
• 150IU
• Others

By Application

• Infertility Treatment
• Assisted Reproductive Technology

Global Urinary Follicle-Stimulating Hormone Market Report by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa